Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the ...

Shares of Merck & Co. Inc. MRK rallied 1.64% to $128.86 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.45% to 7,503.85 and ...

Merck cited business reasons for the discontinuation of the investigational drug.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its first-quarter 2025 sales and earnings conference call with institutional investors ...

Merck & Co., Inc. (NYSE: MRK) has had a fantastic six months, seeing its share price go up nearly 50%. The company has a valuable portfolio of assets that will enable strong shareholder returns, ...

AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China rights to a late-phase challenger to Merck & ...

Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus ...

Mestag Therapeutics has been working to change how fibroblasts are activated and how they expand. Now, Merck & Co. wants in—penning a $1.9 billion biobucks deal to collaborate on new therapies for ...

Merck (MRK) closed the most recent trading day at $128.66, moving +2.56% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.05%. Meanwhile, the Dow lost ...

Germany’s Merck KGaA will buy Bio-Techne Corp. in a deal worth $11.3 billion, one of the largest acquisitions in Minnesota history. The sale follows investor pressure on Minneapolis-based Bio-Techne, ...

Merck & Co. said a late-stage study of its autoimmune drug candidate tulisokibart in ulcerative colitis hit its key goals. Merck on Monday said the Phase 3 induction-only study met its primary ...